Provectus Case Studies Secure Data Infrastructure for Microbiome Research: A Case Study on Second Genome

Edit This Case Study Record

	Secure Data Infrastructure for Microbiome Research: A Case Study on Second Genome Provectus

Secure Data Infrastructure for Microbiome Research: A Case Study on Second Genome

Provectus

Technology Category	Analytics & Modeling - Machine Learning Platform as a Service (PaaS) - Application Development Platforms
Applicable Industries	Cement Pharmaceuticals
Applicable Functions	Product Research & Development Quality Assurance
Use Cases	Construction Management Infrastructure Inspection
Services	Cybersecurity Services Data Science Services
Challenge	Second Genome, a biotechnology company, was seeking to accelerate and scale its microbiome drug discovery and development. The company wanted to improve data ingestion and staging, and refine the codebase of its data platform. Operating in a highly regulated pharmaceutical industry, Second Genome needed to enhance data security compliance to create a safe drug research and development environment for its clients and partners. The company was also looking to handle microbiome data more efficiently to speed up microbial research, drug trials, and discovery. As part of the healthcare industry's transformation towards personalized medicine, Second Genome was aiming to identify responder/non-responder populations and determine the optimal approach to therapy. The challenge was to enhance its data platform to make it faster, more scalable, secure, and compliant. Read More
About Customer	Second Genome is a biotechnology company that extracts microbial genetic insights to make transformational precision therapies and biomarkers through clinical development and commercialization. It uses machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis, and CRISPR, coupled with traditional drug development approaches, to build a proprietary microbiome-based drug discovery and development platform. The company collaborates with industry, academia, and government to optimize its microbiome platform. Gilead Sciences, Inc, one of Second Genome’s strategic partners, is using the platform and comprehensive data sets to identify novel biomarkers for clinical responses to their investigative medicines. Read More
Solution	Second Genome partnered with Provectus to revamp data ingestion and staging of the data pipeline, and to make improvements to its current codebase. A new secure cloud-native data infrastructure on AWS was built in close collaboration with the Second Genome team. It was designed as fully automated, with CI/CD in place, and in line with AWS security guidelines for healthcare data. Provectus reviewed the data ingestion and staging portions of the data pipeline of Second Genome’s data platform, addressing issues such as data quality, error monitoring and logging, handling of hard-coded variables, and running API tests on sample data. DevOps best practices were applied to automate patch management, centralized logging and disaster recovery, and to introduce and improve CI/CD. Data in transit and at rest were secured in Amazon S3 with TLS, and all open security groups were eliminated, with MFA ensured for most users. Read More Log in to view content
Contents

Technology Category

Analytics & Modeling - Machine Learning

Platform as a Service (PaaS) - Application Development Platforms

Applicable Industries

Cement

Pharmaceuticals

Applicable Functions

Product Research & Development

Quality Assurance

Use Cases

Construction Management

Infrastructure Inspection

Services

Cybersecurity Services

Data Science Services

Challenge

Second Genome, a biotechnology company, was seeking to accelerate and scale its microbiome drug discovery and development. The company wanted to improve data ingestion and staging, and refine the codebase of its data platform. Operating in a highly regulated pharmaceutical industry, Second Genome needed to enhance data security compliance to create a safe drug research and development environment for its clients and partners. The company was also looking to handle microbiome data more efficiently to speed up microbial research, drug trials, and discovery. As part of the healthcare industry's transformation towards personalized medicine, Second Genome was aiming to identify responder/non-responder populations and determine the optimal approach to therapy. The challenge was to enhance its data platform to make it faster, more scalable, secure, and compliant.

About Customer

Second Genome is a biotechnology company that extracts microbial genetic insights to make transformational precision therapies and biomarkers through clinical development and commercialization. It uses machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis, and CRISPR, coupled with traditional drug development approaches, to build a proprietary microbiome-based drug discovery and development platform. The company collaborates with industry, academia, and government to optimize its microbiome platform. Gilead Sciences, Inc, one of Second Genome’s strategic partners, is using the platform and comprehensive data sets to identify novel biomarkers for clinical responses to their investigative medicines.

Solution

Second Genome partnered with Provectus to revamp data ingestion and staging of the data pipeline, and to make improvements to its current codebase. A new secure cloud-native data infrastructure on AWS was built in close collaboration with the Second Genome team. It was designed as fully automated, with CI/CD in place, and in line with AWS security guidelines for healthcare data. Provectus reviewed the data ingestion and staging portions of the data pipeline of Second Genome’s data platform, addressing issues such as data quality, error monitoring and logging, handling of hard-coded variables, and running API tests on sample data. DevOps best practices were applied to automate patch management, centralized logging and disaster recovery, and to introduce and improve CI/CD. Data in transit and at rest were secured in Amazon S3 with TLS, and all open security groups were eliminated, with MFA ensured for most users.

Impact #1	The new data infrastructure for the Microbiome Drug Discovery and Development Platform enabled Second Genome to run large-scale projects in a secure compliant environment. This fast, scalable data platform makes it easier for Second Genome to partner with premium biopharma companies, to develop novel therapeutics. The data infrastructure meets the strict requirements and high standards of AWS for security and operational efficiency in the cloud. Thanks to the new secure cloud-native data infrastructure on AWS, Second Genome is now able to more easily onboard premium pharmaceutical companies to its platform. The partners of Second Genome can now discover, develop, and test drugs much faster and on an industrial scale, without having to worry about the security of their research.

Impact #1

The new data infrastructure for the Microbiome Drug Discovery and Development Platform enabled Second Genome to run large-scale projects in a secure compliant environment. This fast, scalable data platform makes it easier for Second Genome to partner with premium biopharma companies, to develop novel therapeutics. The data infrastructure meets the strict requirements and high standards of AWS for security and operational efficiency in the cloud. Thanks to the new secure cloud-native data infrastructure on AWS, Second Genome is now able to more easily onboard premium pharmaceutical companies to its platform. The partners of Second Genome can now discover, develop, and test drugs much faster and on an industrial scale, without having to worry about the security of their research.

Benefit #1	Enabled Second Genome to run petabyte-scale projects for biomarker research, drug trials, and drug development
Benefit #2	Fully automated data pipelines with CI/CD in place
Benefit #3	Data in transit and at rest were secured in Amazon S3 with TLS

Benefit #1

Enabled Second Genome to run petabyte-scale projects for biomarker research, drug trials, and drug development

Benefit #2

Fully automated data pipelines with CI/CD in place

Benefit #3

Data in transit and at rest were secured in Amazon S3 with TLS

Download PDF Version

Overview

Secure Data Infrastructure for Microbiome Research: A Case Study on Second Genome

Operational Impact

Quantitative Benefit